Who
Thomas Richard Kassberg
Director
Company insider
Files Form 4 as: Director, Passage Bio; Cbo & EVP, Ultragenyx Pharmaceutical; SVP-Corp. Dev.& Comm. Oper., Intermune.
In numbers
- Trades disclosed
- 114
- Buys
- 1
- Sells
- 32
- Bought
- $32K
- Sold
- $10.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 16 Jan 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —143,789 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $254K6,028 at $42.10 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code F | $22K508 at $42.92 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —18,443 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —174,139 at $0.00 | filing |
| 11 Mar 2024filed 12 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $575K11,509 at $49.93 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —31,400 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —17,800 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —957 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code F | $15K274 at $53.69 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $54K1,011 at $53.76 | filing |
| 23 Oct 2023filed 24 Oct 2023 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code M | —39,878 at $0.00 | filing |
| 23 Oct 2023filed 24 Oct 2023 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code M | $274K39,878 at $6.86 | filing |
| 23 Oct 2023filed 24 Oct 2023 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1.3M39,878 at $32.78 | filing |
| 1 Mar 2023filed 3 Mar 2023 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —39,400 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —2,663 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $89K1,968 at $45.27 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Thomas Richard Kassberg; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.